You are here: Home: CCU 5 | 2005: Neal J Meropol, MD: Select publications
Select publications
Arkenau H et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first-line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy. Presentation. ASCO 2005;Abstract 3507.
Baddi L, Benson A 3rd. Adjuvant therapy in stage II colon cancer: Current approaches. Oncologist 2005;10(5):325-31. No abstract available
Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45. Abstract
De Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of Stage II and Stage III colon cancer: Efficacy results with a median follow-up of 4 years. Presentation. ASCO 2005;Abstract 3501.
Giantonio BJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presentation. ASCO 2005;Abstract 2.
Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Presentation. ASCO 2005;Abstract 3515.
Kabbinavar F et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract
Lenz HJ et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Presentation. ASCO 2004;Abstract 3510.
Mancuso A, Sternberg CN. Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice? Crit Rev Oncol Hematol 2005;55(1):67-81. Abstract
Saltz LB et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presentation. ASCO 2005;Abstract 3508.
Starling N, Cunningham D. Cetuximab in previously treated colorectal cancer. Clin Colorectal Cancer 2005;5(Suppl 1):28-33. Abstract
Wolmark N et al. A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Presentation. ASCO 2005;Abstract LBA3500.
|
